CTOs on the Move

Aldagen

www.aldagen.com

 
Aldagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aldagen.com
  • 2810 Meridian Pkwy Ste 148
    Durham, NC USA 27713
  • Phone: 919.484.2571

Executives

Name Title Contact Details

Similar Companies

Aditx Therapeutics

Prolonging Life and Enhancing its Quality Technology to improve the health of your immune system Learn more about our technology AditxtScore™ AditxtReprogramming™ AditxtScore™

13Therapeutics Inc

13Therapeutics Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncothyreon

Oncothyreon is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry`s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma`s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson`s Imbruvica, Astellas` and Pfizer`s Xtandi, Biogen`s Tysabri, Johnson & Johnson`s Tremfya, Gilead`s Trodelvy, Merck`s Januvia, Novartis` Promacta, Vertex`s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.

Brammer Bio

Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications. Along with process and analytical development and regulatory support we enable large pharma and biotech clients to accelerate the delivery of novel medicines and improve patient health. Brammer Bio occupies 45,000 ft2 of process development and phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 ft2 facility in Lexington, MA, with plans to build-out large-scale, phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and QC and analytical laboratories for clinical and commercial launch services.